Know your peptides before you buy them.

FDA advisory panel backs BPC-157, KPV, TB-500 and MOTS-C — but nothing is approved

The Pharmacy Compounding Advisory Committee voted 8–6 with one abstention in favour of both BPC-157 (reviewed for ulcerative colitis) and KPV (wound treatment and inflammatory conditions), and also voted in favour of TB-500 (8–6, one abstention) and MOTS-C (7–5, two abstentions). The votes recommend adding these substances to the 503A Bulks List, which governs what compounding pharmacies may prepare.

What it is not: the panel does not decide. The votes are non-binding, the FDA has not ruled, and even a favourable decision requires a rulemaking process before anything formally changes. None of these compounds became FDA-approved drugs today.

Day two: Semax and Epitalon recommended, DSIP rejected by a single vote

On July 24 the same panel voted to recommend Semax (8–5) and Epitalon (7–4, one abstention) for the 503A Bulks List, and declined to recommend Emideltide — DSIP — by one vote. That closes the meeting at six of seven recommended.

The part that matters most: the FDA's own scientific staff had recommended against all seven substances. The committee went the other way on six of them. That is unusual, and it is why this meeting is being written about as a turning point rather than a formality.

What it is not: still not a decision. The recommendations are non-binding, formal rulemaking has not begun, and nothing became legal to compound this week that was not legal the week before. If the FDA proceeds, the realistic timeline runs into 2027.

What actually changed in April, and what didn't

Earlier this year several peptides came off the FDA's Category 2 list — the group flagged with enough concern to restrict compounding. Coming off Category 2 is not the same as being cleared for use; it moved these compounds into a reviewable position, which is why this week's meeting is happening at all.